Abstract

BackgroundEfficacy and safety of intravenously (IV) administered tocilizumab (TCZ) in rheumatoid arthritis (RA) has been shown. Recently, efficacy and safety was confirmed for subcutaneous (SC) administration of TCZ.1 The possible...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.
Bruno Tassone ... Domenico Laganà
Journal of medical virology | VOL. 93
Bruno Tassone, et. al.Bruno Tassone ... Domenico Laganà
30 Sep 2020
POS0799 THE EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
K J Warrington ... S Mohan
-
K J Warrington, et. al.K J Warrington ... S Mohan
19 May 2021
SAT0105 Summacta: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy Of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients With Moderate to Severe Ra
G R Burmester ... E Mysler
Annals of the Rheumatic Diseases | VOL. 72
G R Burmester, et. al.G R Burmester ... E Mysler
01 Jun 2013
SAT0248 CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE
Christine Birchwood ... Jinglan Pei
-
Christine Birchwood, et. al.Christine Birchwood ... Jinglan Pei
27 May 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers